Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析

◆英語タイトル:Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH6319FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Merck & Co Inc (MRK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products like vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc Key Recent Developments

Apr 01,2021: Merck Completes Acquisition of Pandion Therapeutics
Mar 30,2021: Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 29,2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24,2021: Merck appoints Caroline Litchfield Chief Financial Officer
Mar 17,2021: M2GEN announces new collaboration with Merck to advance cancer therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Merck & Co Inc – Key Facts
Merck & Co Inc – Key Employees
Merck & Co Inc – Key Employee Biographies
Merck & Co Inc – Major Products and Services
Merck & Co Inc – History
Merck & Co Inc – Company Statement
Merck & Co Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Joint Venture
Section 2 – Company Analysis
Company Overview
Merck & Co Inc – Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Others
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Asia Pacific (other than Japan and China)
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe, Middle East and Africa
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Merck & Co Inc – Corporate Strategy
Merck & Co Inc – SWOT Analysis
SWOT Analysis – Overview
Merck & Co Inc – Strengths
Merck & Co Inc – Weaknesses
Merck & Co Inc – Opportunities
Merck & Co Inc – Threats
Merck & Co Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Oil & Gas Financial Deals and Alliances
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 29, 2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24, 2021: Merck appoints Caroline Litchfield Chief Financial Officer
Mar 17, 2021: M2GEN announces new collaboration with Merck to advance cancer therapies
Mar 17, 2021: Mike Nally to leave Merck; Frank Clyburn to lead all Merck human health
Mar 15, 2021: Gilead and Merck announce agreement to jointly develop and commercialize long-acting, Investigational treatment combinations of Lenacapavir and Islatravir in HIV
Mar 03, 2021: Merck to Present at the Barclays Global Healthcare Conference
Mar 03, 2021: GPHL and Merck build strategic partnership on business innovation and development in GBA
Mar 02, 2021: Merck announces fifth round of global grants to tackle maternal mortality and promote health equity worldwide
Mar 02, 2021: Biden’s latest announcement about invoking DPA
Feb 09, 2021: Merck mourns Hans Joachim Langmann
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Merck & Co Inc, Key Facts
Merck & Co Inc, Key Employees
Merck & Co Inc, Key Employee Biographies
Merck & Co Inc, Major Products and Services
Merck & Co Inc, History
Merck & Co Inc, Subsidiaries
Merck & Co Inc, Affiliate
Merck & Co Inc, Joint Venture
Merck & Co Inc, Key Competitors
Merck & Co Inc, Ratios based on current share price
Merck & Co Inc, Annual Ratios
Merck & Co Inc, Annual Ratios (Cont...1)
Merck & Co Inc, Annual Ratios (Cont...2)
Merck & Co Inc, Interim Ratios
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ATGen Co Ltd (182400):製薬・医療:M&Aディール及び事業提携情報
    Summary ATGen Co Ltd (ATGen) is a manufacturer and supplier of proteins and monoclonal antibodies. The company offers neuroproteins, enzymes, heat shock proteins, ubiquitins, cancer related proteins, antibodies, viral antigens and hormones. It conducts research and development of medicines based on …
  • ProQR Therapeutics NV (PRQR):製薬・医療:M&Aディール及び事業提携情報
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Getinge AB (GETI B)-医療機器分野:企業M&A・提携分析
    Summary Getinge AB (Getinge) is a global medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia …
  • Midsona AB (MSON B):企業の財務・戦略的SWOT分析
    Summary Midsona AB (Midsona), is a healthcare products manufacturing company that provides personal care products, health foods, and hygiene products. The company’s products include superfood, sports nutrition, dietary supplements, nutritional supplements, organic food, herbal teas, skin-care and be …
  • Eureka Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Eureka Therapeutics Inc (Eureka Therapeutics) is a clinical stage biotechnology company which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological can …
  • Norwegian Energy Company ASA (NOR):石油・ガス:M&Aディール及び事業提携情報
    Summary Norwegian Energy Company ASA (Noreco) is an oil and gas company that offers exploration and development services. The company explores, produces and develops oil, gas, and natural gas liquids deposit properties. It operates through ongoing and planned exploration wells such as PL616 Haribo a …
  • Caspian Energy Inc. (CKZ.H):石油・ガス:M&Aディール及び事業提携情報
    Summary Caspian Energy Inc (CEI) is an independent upstream oil and gas company. It carries out the exploration, development, and production of oil and gas. and the company, along with its subsidiaries hold interests in Aral Petroleum Capital LLP, which holds an exclusive license to explore and deve …
  • M.M.Warburg & Co Kgaa
    M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report Summary M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nilkamal Ltd:企業の戦略・SWOT・財務情報
    Nilkamal Ltd - Strategy, SWOT and Corporate Finance Report Summary Nilkamal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Urban One, Inc.:企業の戦略・SWOT・財務分析
    Urban One, Inc. - Strategy, SWOT and Corporate Finance Report Summary Urban One, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Charkit Chemical Company LLC:企業の戦略・SWOT・財務情報
    Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report Summary Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)-製薬・医療分野:企業M&A・提携分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) manufactures and markets traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, western medicines, dietary supplements, pharmaceutical raw materials an …
  • Illumina Inc (ILMN)-医療機器分野:企業M&A・提携分析
    Summary Illumina, Inc. (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; micro …
  • Taisho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products such as lipovitan D, riup, clarith, z …
  • Hooker Furniture Corp (HOFT):企業の財務・戦略的SWOT分析
    Hooker Furniture Corp (HOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Carraro Spa:企業の戦略・SWOT・財務情報
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Simon Property Group Inc (SPG):企業の財務・戦略的SWOT分析
    Simon Property Group Inc (SPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Biomerica Inc (BMRA):企業の財務・戦略的SWOT分析
    Biomerica Inc (BMRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Martin Midstream Partners LP (MMLP):石油・ガス:M&Aディール及び事業提携情報
    Summary Martin Midstream Partners LP (Martin Midstream) is a midstream service provider that carries out the transportation, storage and distribution of petroleum products and by-products. Its service offerings include terminalling, transportation, distribution, and midstream logistical services, be …
  • Plus Therapeutics Inc (PSTV):企業の財務・戦略的SWOT分析
    Plus Therapeutics Inc (PSTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆